Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the very first quarter of 2021.
The analysts price targets range from a high of $101 to a low of sixty one dolars.
From the latest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, medical relief abilities. The Corporate segment involves in providing management and administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.